van Dieijen-Visser M P, van Wersch J, Brombacher P J, Rosing J, Hemker H C, van Dieijen G
Haemostasis. 1982;12(3):241-55. doi: 10.1159/000214679.
Spectrophotometric methods were used to assay the clotting factors II, VII, IX and X in plasma of 33 subjectively healthy human donors and in plasma of 98 patients receiving long-term oral anticoagulant therapy. In 33 normal subjects the interindividual variations in the plasma activities of the clotting factors II, VII, IX and X are respectively 12.2, 21.4, 11.0 and 15.0%. After correction for the assay variations the remaining biological variations are respectively 11.7, 21.2, 9.7 and 14.8%. Plasma from 98 patients receiving long-term anticoagulant therapy was assayed with 'Thrombotest', a clotting test in whole blood introduced by Owren and in these plasmas the activity of each of the vitamin K-dependent factors was assayed with spectrophotometric methods. For the clotting factors IX and VII, novel spectrophotometric methods were applied and the plasma activities thus measured were compared to results obtained with factor IX and VII clotting assays. Chromogenic activities of the different factors were correlated among each other and with 1/Thrombotest values. When the therapeutic range for Thrombotest values is set between 5 and 12.5% the corresponding therapeutic ranges for the activity of the factors II, VII, IX and X are respectively 12.6-36.1, 27.0-52.3, 23.1-49.3 and 18.9-36.2% (expressed as a percentage of the activity in normal pool plasma). The chromogenic assays for the factors II, VII, IX and X provide the same information on the therapeutic state of the patients in respectively 86.7, 78.6, 81.6 and 89.8% of the cases. Finally we discuss the suitability of the different assays to monitor oral anticoagulant therapy.
采用分光光度法测定了33名主观健康的人体供血者血浆以及98名接受长期口服抗凝治疗患者血浆中的凝血因子II、VII、IX和X。在33名正常受试者中，凝血因子II、VII、IX和X的血浆活性个体间差异分别为12.2%、21.4%、11.0%和15.0%。校正测定差异后，剩余的生物学差异分别为11.7%、21.2%、9.7%和14.8%。采用Owren介绍的全血凝血试验“血栓试验”对98名接受长期抗凝治疗患者的血浆进行了检测，并用分光光度法测定了这些血浆中各维生素K依赖因子的活性。对于凝血因子IX和VII，应用了新的分光光度法，并将由此测得的血浆活性与因子IX和VII凝血试验结果进行了比较。不同因子的显色活性相互之间以及与1/血栓试验值相关。当血栓试验值的治疗范围设定在5%至12.5%之间时，因子II、VII、IX和X活性的相应治疗范围分别为12.6 - 36.1%、27.0 - 52.3%、23.1 - 49.3%和18.9 - 36.2%（以正常混合血浆中活性的百分比表示）。因子II、VII、IX和X的显色测定分别在86.7%、78.6%、81.6%和89.8%的病例中提供了关于患者治疗状态的相同信息。最后，我们讨论了不同检测方法用于监测口服抗凝治疗的适用性。
